Skip to main content
. 2021 Sep 9;12:621090. doi: 10.3389/fimmu.2021.621090

Figure 3.

Figure 3

SJL/J mice chronically treated with PLX5622 exhibit exacerbated TMEV-induced demyelinating disease. (A) SJL/J mice were treated with a PLX5622-supplemented or control diet seven days prior to i.c. TMEV infection and sacrificed at 103 DPI for analysis. (B) Representative flow plots and quantification of CNS microglia (n = at least 6 mice per group). (C) Survival, (D) clinical score, and (E) weight change corresponding to (A) (n = 20 mice per group). (F) Representative luxol fast blue staining and (G) TMEV antigen staining (arrows highlight positive staining) in thoracic spinal cord cross sections and quantification (n = 6 mice per group, at least 5 sections per mouse). Data are presented as mean ± SEM. *P ≤ 0.05, ****P ≤ 0.0001, ns, not significant; Student t test for (B, F, G), log-rank test for (C), and two-way ANOVA for (D, E).